Printer Friendly

FUJISAWA ANNOUNCES REORGANIZATION AND SENIOR EXECUTIVE APPOINTMENTS

FUJISAWA ANNOUNCES REORGANIZATION AND SENIOR EXECUTIVE APPOINTMENTS
 DEERFIELD, Ill., June 25 /PRNewswire/ -- A reorganization and series of senior executive appointments were announced today by Fujisawa USA, Inc., a subsidiary of Fujisawa Pharmaceutical Co., Ltd., the third leading pharmaceutical company in Japan.
 A centralized Fujisawa USA Operations group has been formed as an independent unit from both the Fujisawa Pharmaceutical Company unit and the Lyphomed unit. The new Operations group will manufacture products for both units and becomes a unit of Fujisawa USA, Inc.
 Nelson Levy, Ph.D., M.D., became president of the Fujisawa Pharmaceutical Company unit in May.
 Theron Odlaug, Ph.D., has been named president of the Operations group. He will be responsible for manufacturing, quality assurance/quality control, formulations, information systems and regulatory affairs.
 Mr. John Fowler has been named president of the Lyphomed unit. He will be responsible for marketing and sales, customer operations and new business development.
 Mr. Takashi Aoki, chairman and chief executive officer of Fujisawa USA, Inc., was appointed vice chairman of Fujisawa Pharmaceutical Co., Ltd. Mr. Aoki continues his responsibilities with Fujisawa USA and also continues as a representative director on the board of the parent company.
 "The formation of the Operations group is a direct reflection of Fujisawa's commitment to assume a leadership role of superior quality and integrity within the pharmaceutical industry," Mr. Aoki said. "We also believe the appointment of the three senior executives will help Fujisawa USA achieve the best product and process quality and become a premier pharmaceutical company."
 -- Dr. Nelson Levy
 Dr. Nelson Levy received his M.D. from Columbia University College of Physicians and Surgeons in 1967 after completing his undergraduate studies at Yale University.
 After receiving a Ph.D. in immunology in 1973 from Duke University, he joined the faculty of the Duke University Medical Center, where he was an associate professor of immunology. He is the author or co-author of more than 130 scientific publications.
 Dr. Levy was named director of antibiotics and natural products at Abbott Laboratories in 1981, and in the same year became vice president of pharmaceutical research. He joined CoreTechs Corporation in 1984 and became chief executive officer in 1986.
 Dr. Levy and his wife live in Lake Forest, Ill. They have six sons.
 -- Theron Odlaug
 Dr. Theron Odlaug, who will become president of operations effective July 27, was previously responsible for North American Regional Coordination with Bayer AG in Leverkusen, Germany.
 Dr. Odlaug was with Miles Inc. (Bayer's U.S. subsidiary) from 1986 to 1991, serving as group vice president of the diagnostics business group since 1989. Before that he was with Baxter Healthcare Corp. from 1978 through 1986.
 He received a bachelor's degree in biology in 1971 and a master's in biology in 1973, both from the University of Missouri, and a doctorate in environmental health from the University of Minnesota in 1978. He is the author of a number of scientific publications.
 Dr. Odlaug will relocate to the Deerfield area with his wife and three children.
 -- John Fowler
 Before joining Fujisawa USA as assistant to the chairman and CEO in January, 1991, Mr. Fowler was vice president of marketing and sales for Boots Pharmaceuticals Incorporated (Boots U.S.A. subsidiary). He began his career with Baxter International in 1973.
 Mr. Fowler received a bachelor's degree in business administration from Rutgers University in 1966 and completed the advanced management program at the


Harvard Business School in 1988. He served as a Captain in the U.S. Marine Corps and is a combat veteran of Vietnam, where he received several personal and numerous unit awards.
 He lives in Libertyville, Ill. with his wife and five children.
 -0- 6/25/92
 /CONTACT: Bob Schwadron of Hill and Knowlton, 212-697-5600, or 212-210-8730, for Fujisawa/ CO: Fujisawa USA, Inc.; Fujisawa Pharmaceutical Co., Ltd. ST: Illinois IN: MTC SU: PER


AH -- NY083 -- 4023 06/25/92 18:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 25, 1992
Words:647
Previous Article:LUCAS WINS CONTRACT ON PATRIOT MISSILE
Next Article:GARY H. BECHTEL APPOINTED TO PROJECT CALIFORNIA PANEL
Topics:


Related Articles
A. L. LABORATORIES ANNOUNCES KEY MANAGEMENT APPOINTMENTS AT ITS BARRE-NATIONAL SUBSIDIARY
FUJISAWA USA ANNOUNCES INTEGRATION OF NATIONAL ACCOUNTS DEPARTMENT
FUJISAWA USA APPOINTS HERRICK TO MARKET PLANNING POST
FUJISAWA USA PREPARES FOR ADENOSCAN(R) APPROVAL, PURSUES COMPLAINT AGAINST MEDCO RESEARCH AND ABBOTT
FUJISAWA APPOINTS NEW PRESIDENT
FUJISAWA USA, INC. APPOINTS NEW CEO
RPR Implements New Management Structure in Japan
AAI Welcomes George S. Zorich, R.Ph. as Vice President, Marketing and Sales
Fujisawa Healthcare, Inc. Appoints New CEO.
Renowned Transplant Physician M. Roy First, M.D. to Join Fujisawa Healthcare, Inc.'s Immunology Group.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters